Quantum Biopharma Returns to Nasdaq Compliance and Completes Debt Settlements

Quantum BioPharma Ltd. has received formal notification from Nasdaq confirming its compliance with the minimum bid price requirement as per Rule 5550(a)(2). This ensures the company's continued listing and trading on the Nasdaq exchange.

The company also announced the completion of debt settlements amounting to $450,000 with executives Anthony Durkacz, Zeeshan Saeed, and Donal Carroll. These settlements involved issuing 248,160 Class B Shares at $5.44 per share.

The debt settlements were classified as "related party transactions" and executed under exemptions in sections 5.5(a) and 5.7(1)(a) of MI 61-101. Further details will be in a material change report filed by the company.

In accordance with National Instrument 62-103, Early Warning Reports were filed by Xorax Family Trust and Fortius Research and Trading Corp. due to their debt settlements and acquisition of Class B Shares. Both entities confirmed their future investment will adjust as required by market conditions.